BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33535987)

  • 1. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.
    Wang X; Wang H; Wang H; Huang J; Wang X; Jiang Z; Tan L; Jiang D; Hou Y
    BMC Cancer; 2021 Feb; 21(1):111. PubMed ID: 33535987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy.
    Chao YK; Chang CB; Chuang WY; Wen YW; Chang HK; Tseng CK; Yeh CJ; Liu YH
    Medicine (Baltimore); 2015 Aug; 94(34):e1407. PubMed ID: 26313788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Hatogai K; Fujii S; Kojima T; Daiko H; Kadota T; Fujita T; Yoshino T; Doi T; Takiguchi Y; Ohtsu A
    J Surg Oncol; 2016 Mar; 113(4):390-6. PubMed ID: 27100024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
    BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.
    Kadota T; Hatogai K; Yano T; Fujita T; Kojima T; Daiko H; Fujii S
    Cancer Sci; 2018 Jun; 109(6):2046-2055. PubMed ID: 29601131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single-center experience.
    Lombardi PM; Mazzola M; Achilli P; Aquilano MC; De Martini P; Curaba A; Gualtierotti M; Bertoglio CL; Magistro C; Ferrari G
    J Surg Oncol; 2021 Mar; 123(4):923-931. PubMed ID: 33497471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy.
    Guo K; Cai L; Zhang Y; Zhu JF; Rong TH; Lin P; Hao CL; Wang WP; Li Z; Zhang LJ
    Chin J Cancer; 2012 Aug; 31(8):399-408. PubMed ID: 22572013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
    Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
    Gao L; Hong ZN; Wu L; Yang Y; Kang M
    Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of patients with esophageal squamous cell carcinoma who achieve major histopathological response after neoadjuvant chemoradiotherapy.
    Chao YK; Chuang WY; Chang HK; Tseng CK; Yeh CJ; Liu YH
    Eur J Surg Oncol; 2017 Jan; 43(1):234-239. PubMed ID: 27462024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral
    Yamamura K; Izumi D; Kandimalla R; Sonohara F; Baba Y; Yoshida N; Kodera Y; Baba H; Goel A
    Clin Cancer Res; 2019 Oct; 25(20):6170-6179. PubMed ID: 31358543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
    Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
    Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
    BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) With Lymph Node Status (ypN-Category) Results in Better Prognostication Than ypTNM Stage Groups After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
    Wong IYH; Chung JCY; Zhang RQ; Gao X; Lam KO; Kwong DLW; Chao YK; Law SYK
    Ann Surg; 2022 Nov; 276(5):784-791. PubMed ID: 35876374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.